# A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06119581/  
OnCo record `nct06119581` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olomorasib, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.

## Summary

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06119581 by Eli Lilly and Company, with 1264 participants planned, started 2023-12-21 and due to reach its primary completion in 2027-11. Interventions recorded: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin and Pemetrexed.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06119581
- Phase: 3
- Setting: SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
- Sponsor: Eli Lilly and Company
- Enrolled: 1264

## Sources

- ClinicalTrials.gov NCT06119581: https://clinicaltrials.gov/study/NCT06119581

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct06119581.json